CardioExchange Archive

June 3rd, 2013

How Do Patients with CAD Fare After TAVR?

Sachin Goel, MD and Erica Sarah Spatz, MD, MHS

Sachin Goel discusses his research group’s literature review focusing on patients with coronary artery disease who are evaluated for — and those who undergo — transcatheter aortic valve replacement.

---

March 11th, 2013

Hoping for Good Data from Partner II B: Blogging from ACC.13

Megan Coylewright, MD MPH

Walking the walk on TAVR

---

February 20th, 2013

Small Study Explores Expanded Use for TAVI in Native Valve Aortic Regurgitation

Larry Husten, PHD

As transcatheter aortic valve implantation (TAVI) gains increasing acceptance, cardiologists and surgeons are exploring additional patient populations who may benefit from the procedure. A new paper in the Journal of the American College of Cardiology provides the first look at the use of TAVI in the small but important group of patients with pure, severe native aortic […]

---

February 12th, 2013

ACC and STS Break New Ground to Test TAVR for Unapproved Uses

Larry Husten, PHD

In a startling break with tradition, the American College of Cardiology (ACC) and the Society of Thoracic Surgeons (STS) will manage and run their own clinical trials testing expanded uses for transcatheter aortic valve replacement (TAVR). The two medical groups have recently been granted an investigational device exemption (IDE) by the FDA for one such […]

---

October 24th, 2012

TCT: Impressive Survival Benefit for TAVR in Inoperable Patients at 3 Years

Larry Husten, PHD

At the TCT meeting in Miami, Murat Tuzcu presented the latest findings from the PARTNER B trial comparing transcatheter aortic valve replacement (TAVR) with standard therapy in patients who are not considered eligible for surgical valve replacement. At 3 years, the mortality advantage continued to grow for TAVR over standard therapy. All-cause mortality at 3 years: 80.9% […]

---

October 22nd, 2012

FDA Approves the Sapien Transcatheter Heart Valve for High-Risk Patients

Larry Husten, PHD

The FDA today approved an expanded indication for Edwards Lifesciences’ Sapien transcatheter heart valve (THV). The device can now be implanted in patients who are eligible for aortic valve replacement surgery but are at high risk for serious surgical complications or death. Previously the Sapien valve was approved only for use in patients who were […]

---

August 6th, 2012

TAVR and the Price of Innovation

Daniel Mark, Richard A. Lange, MD, MBA and L. David Hillis, MD

In an article published in Circulation, Daniel Mark and Robert Mentz of the Duke Clinical Research Institute and University Medical Center examine the economic and policy implications of the recent validation of transcatheter aortic valve replacement (TAVR) in the PARTNER trials. CardioExchange is fortunate and pleased to present Dr. Mark’s responses to questions about his […]

---

July 31st, 2012

TAVI: Belgian Researchers Slam Evidence Base and Overuse in Europe

Larry Husten, PHD

The growing and enthusiastic adoption of transcatheter aortic valve implantation (TAVI) in Europe has no justification, according to three researchers who performed a health technology assessment for the Belgian government. In a paper published in BMJ, the authors from the Belgian Health Care Knowledge Centre conclude that TAVI should only be used in patients “who are deemed inoperable […]

---

July 16th, 2012

The Name Game: Why Did “TAVI” Suddenly Become “TAVR”?

Larry Husten, PHD

One of the great, unexplained mysteries of the cardiology world in recent years is the sudden name change from TAVI  (transcatheter aortic valve implantation), which had been the universally-used name for the procedure during most of its development period, to TAVR  (transcatheter aortic valve replacement) about the time when the procedure edged closer to U.S. approval. Now, in […]

---

June 26th, 2012

Unlikely PARTNERs Support TAVR

Richard A. Lange, MD, MBA

The FDA approval of TAVR and the design of postmarketing surveillance involved a remarkable degree of collaboration and cooperation among the stakeholders. What to do while we wait for data to accumulate?

---